Leukotriene pathway in sickle cell disease: A potential target for directed therapy

Expert Review of Hematology

Volumn 2, Issue 1, 2009, Pages 57-68

  Knight Perry, Jessica ^a   Debaun, Michael R ^a   Strunk, Robert C ^a   Field, Joshua J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Asthma; Inflammation; Leukotriene; Sickle cell disease; Vaso occlusion

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BIOLOGICAL MARKER; DEXAMETHASONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR; METHYLPREDNISOLONE; MONTELUKAST; PADGEM PROTEIN; SECRETORY PHOSPHOLIPASE A2; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ZAFIRLUKAST; ZILEUTON;

ACUTE CHEST SYNDROME; ALOX 5 GENE; ASTHMA; AVASCULAR NECROSIS; BIOSYNTHESIS; BLOOD VESSEL OCCLUSION; COMORBIDITY; DNA POLYMORPHISM; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; GENE; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; STROKE;

ANEMIA, SICKLE CELL; ANIMALS; HUMANS; LEUKOTRIENES; MOLECULAR TARGETED THERAPY;

EID: 65949112678     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474086.2.1.57     Document Type: Review

References (107)

1. Hassell K. Sickle cell disease population estimation: application of available contemporary data to traditional methods. Presented at: 35th Anniversary Convention of the National Sickle Cell Disease Program. Washington, DC, USA, 17-22 September 2007.
2. Platt OS, Thorington BD, Brambilla DJ et al. Pain in sickle cell disease. Rates and risk factors. N. Engl. J. Med. 325(1), 11-16 (1991).
3. Castro O, Brambilla DJ, Thorington B et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 84(2), 643-649 (1994). (Pubitemid 24215969)
4. Vichinsky EP, Neumayr LD, Earles AN et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N. Engl. J. Med. 342(25), 1855-1865 (2000).
5. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood 108(9), 2923-2927 (2006).
6. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with increased mortality in individuals with sickle cell anemia. Haematologica 92(8), 1115-1118 (2007).
7. Setty BN, Stuart MJ. Eicosanoids in sickle cell disease: potential releVance of neutrophil leukotriene B4 to disease pathophysiology. J. Lab. Clin. Med. 139(2), 80-89 (2002).
8. Jennings JE, Ramkumar T, Mao J et al. Elevated urinary leukotriene E4 levels are associated with hospitalization for pain in children with sickle cell disease. Am. J. Hematol. 83(8), 640-643 (2008).
9. Okpala I. Leukocyte adhesion and the pathophysiology of sickle cell disease. Curr. Opin. Hematol. 13(1), 40-44 (2006).
10. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 11(2), 129-151 (2004).
11. Hoover R, Rubin R, Wise G, Warren R. Adhesion of normal and sickle erythrocytes to endothelial monolayer cultures. Blood 54(4), 872-876 (1979).
12. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle cell anemia: a possible determinant of disease severity. N. Engl. J. Med. 302(18), 992-995 (1980).
13. Hebbel RP, Vercellotti GM. The endothelial biology of sickle cell disease. J. Lab. Clin. Med. 129(3), 288-293 (1997).
14. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N. Engl. J. Med. 337(22), 1584-1590 (1997).
15. Blei F, Fancher T, Guarini L. Elevated levels of circulating molecules of potential endothelial origin in sickle cell disease (abstract). Blood 84(Suppl. 1), 409A (1994).
16. Parsons SF, Lee G, Spring FA et al. Lutheran blood group glycoprotein and its newly characterized mouse homologue specifically bind ?-5 chain-containing human laminin with high affinity. Blood 97(1), 312-320 (2001).
17. Gee BE, Platt OS. Sickle reticulocytes adhere to VCAM-1. Blood 85(1), 268-274 (1995).
18. Kumar A, Eckmam JR, Swerlick RA, Wick TM. Phorbol ester stimulation increases sickle erythrocyte adherence to endothelium: a novel pathway involving -4-1 integrin receptors on sickle reticulocytes and fibronectin. Blood 88(11), 4348-4358 (1996).
19. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol. Oncol. Clin. North Am. 19(5), 771-784 (2005).
20. Gupta K, Gupta P, Solovey A, Hebbel RP. Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. Biochim. Biophys. Acta 1453(1), 63-73 (1999).
21. Wick TM, Moake JL, Udden MM, McIntire LV. Unusually large von Willebrand factor multimers preferentially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells. Am. J. Hematol. 42(3), 284-292 (1993).
22. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 10(3-4), 335-350 (2003).
23. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J. Lab. Clin. Med. 137(6), 398-407 (2001).
24. Antonucci R, Walker R, Herion J, Orringer E. Enhancement of sickle erythrocyte adherence to endothelium by autologous platelets. Am. J. Hematol. 34(1), 44-48 (1990).
25. Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin. Lab. Haematol. 24(2), 81-88 (2002).
26. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson KCA. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J. Lab. Clin. Med. 129, 507-516 (1997).
27. Lum AF, Wun T, Staunton D, Simon SI. Inflammatory potential of neutrophils detected in sickle cell disease. Am. J. Hematol. 76(2), 126-133 (2004).
28. Fadlon E, Vordermeier S, Pearson TC et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 91(1), 266-274 (1998).
29. Lard LR, Mul FP, de Haas M, Roos D, Duits AJ. Neutrophil activation in sickle cell disease. J. Leukoc. Biol. 66(3), 411-415 (1999).
30. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 96(7), 2451-2459 (2000).
31. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc. Natl Acad. Sci. USA 99(5), 3047-3051 (2002).
32. Frenette PS. Sickle cell vasoocclusion: heterotypic, multicellular aggregations driven by leukocyte adhesion. Microcirculation 11(2), 167-177 (2004).
33. West MS, Wethers D, Smith J, Steinberg M. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. J. Clin. Epidemiol. 45(8), 893-909 (1992).
34. Awogu AU. Leucocyte counts in children with sickle cell anaemia usefulness of stable state values during infections. West Afr. J. Med. 19(1), 55-58 (2000).
35. Okpala I. Steady-state platelet count and complications of sickle cell disease. Hematol. J. 3(4), 214-215 (2002).
36. Hedo CC, Aken'ova YA, Okpala IE, Durojaiye AO, Salimonu LS. Acute phase reactants and severity of homozygous sickle cell disease. J. Intern. Med. 233(6), 467-470 (1993).
37. Stuart J, Stone PC, Akinola NO, Gallimore JR, Pepys MB. Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease. J. Clin. Pathol. 47(2), 166-169 (1994).
38. Singhal A, Doherty JF, Raynes JG et al. Is there an acute-phase response in steady-state sickle cell disease? Lancet 341(8846), 651-653 (1993).
39. Croizat H. Circulating cytokines in sickle cell patients during steady state. Br. J. Haematol. 87(3), 592-597 (1994).
40. Francis RB Jr, Haywood LJ. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J. Natl Med. Assoc. 84(7), 611-615 (1992).
41. Malave I, Perdomo Y, Escalona E et al. Levels of tumor necrosis factor-α/cachectin (TNF-α) in sera from patients with sickle cell disease. Acta Haematol. 90(4), 172-176 (1993).
42. Pathare A, Kindi SA, Daar S, Dennison D. Cytokines in sickle cell disease. Hematology 8(5), 329-337 (2003).
43. Kato G, Martyr S, Blackwelder WC et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br. J. Haematol. 130(6), 943-953 (2005).
44. Kinney TR, Sleeper LA, Wang WC et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 103(3), 640-645 (1999).
45. Balkaran B, Char G, Morris JS, Thomas P W, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J. Pediatr. 120(3), 360-366 (1992).
46. Ohene-Frempong K, Weiner SJ, Sleeper LA et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91(1), 288-294 (1998).
47. Miller ST, Sleeper LA, Pegelow CH et al. Prediction of adverse outcomes in children with sickle cell disease. N. Engl. J. Med. 342(2), 83-89 (2000).
48. Platt OS, Brambilla DJ, Rosse WF et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J. Med. 330(23), 1639-1644 (1994).
49. Charache S, Barton FB, Moore RD et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 75(6), 300-326 (1996).
50. Bloom B, Dey AN. Summary health statistics for U.S. children: National Health Interview Survey, 2004. Vital Health Stat. 10 (227), 1-85 (2006).
51. Duckworth L, Hsu L, Feng H et al. Physician-diagnosed asthma and acute chest syndrome: associations with NOS polymorphisms. Pediatr. Pulmonol. 42(4), 332-338 (2007).
52. Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax 60(3), 206-210 (2005).
53. Nordness ME, Lynn J, Zacharisen MC, Scott PJ, Kelly KJ. Asthma is a risk factor for acute chest syndrome and cerebral vascular accidents in children with sickle cell disease. Clin. Mol. Allergy 3(1), 2 (2005).
54. Nandedkar SD, Feroah TR, Hutchins W et al. Histopathology of experimentallyinduced asthma in a murine model of sickle cell disease. Blood 112(6), 2529-2538 (2008).
55. Charache S, Terrin ML, Moore RD et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N. Engl. J. Med. 332(20), 1317-1322 (1995).
56. Styles LA, Lubin B, Vichinsky E et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 89(7), 2554-2559 (1997).
57. Covas DT, de Lucena Angulo I, Vianna Bonini Palma P, Zago MA. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia. Haematologica 89(3), 273-280 (2004).
58. Gambero S, Canalli AA, Traina F et al. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. Eur. J. Haematol. 78(2), 144-151 (2007).
59. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br. J. Haematol. 109(2), 322-327 (2000).
60. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J. 3(4), 215-226 (2003).
61. Belcher JD, Mahaseth H, Welch TE et al. Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am. J. Physiol. Heart Circ. Physiol. 288(6), H2715-H2725 (2005).
62. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N. Engl. J. Med. 330(11), 733-737 (1994).
63. Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT, Buchanan GR. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 92(9), 3082-3089 (1998).
64. Strouse JJ, Hulbert ML, DeBaun MR, Jordan LC, Casella JF. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics 118(5), 1916-1924 (2006).
65. Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 97(7), 1937-1941 (2001).
66. Embury SH, Matsui NM, Ramanujam S et al. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood 104(10), 3378-3385 (2004).
67. Kaul DK, Tsai HM, Liu XD, Nakada MT, Nagel RL, Coller BS. Monoclonal antibodies to aVb3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 95(2), 368-374 (2000).
68. Solovey A, Kollander R, Shet A et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/ reoxygenation and inhibited by lovastatin. Blood 104(3), 840-846 (2004).
69. Peters-Golden M. Expanding roles for leukotrienes in airway inflammation. Curr. Allergy Asthma Rep. 8(4), 367-373 (2008).
70. Peters-Golden M, Henderson WR Jr. Leukotrienes. N. Engl. J. Med. 357(18), 1841-1854 (2007).
71. Rabinovitch N. Urinary leukotriene E4. Immunol. Allergy Clin. North Am. 27(4), 651-664 (2007).
72. Lynch KR, O'Neill GP, Liu Q et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399(6738), 789-793 (1999).
73. Beller TC, Friend DS, Maekawa A, Lam BK, Austen KF, Kanaoka Y. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc. Natl Acad. Sci. USA 101(9), 3047-3052 (2004).
74. Joris I, Majno G, Corey EJ, Lewis RA. The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction. Am. J. Pathol. 126(1), 19-24 (1987).
75. Drazen JM, Austen KF, Lewis RA et al. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc. Natl Acad. Sci. USA 77(7), 4354-4358 (1980).
76. Datta YH, Romano M, Jacobson BC, Golan DE, Serhan CN, Ewenstein BM. Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation 92(11), 3304-3311 (1995).
77. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol. 173(3), 1503-1510 (2004).
78. Woszczek G, Chen LY, Nagineni S et al. Leukotriene D4 induces gene expression in human monocytes through cysteinyl leukotriene type I receptor. J. Allergy Clin. Immunol. 121(1), 215-221 e211 (2008).
79. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B4 receptors. Prostaglandins Leukot. Essent. Fatty Acids 69(2-3), 123-134 (2003).
80. Ford-Hutchinson AW. Leukotriene B4 in inflammation. Crit. Rev. Immunol. 10(1), 1-12 (1990).
81. Friedrich EB, Tager AM, Liu E et al. Mechanisms of leukotriene B4-triggered monocyte adhesion. Arterioscler. Thromb. Vasc. Biol. 23(10), 1761-1767 (2003).
82. Weller CL, Collington SJ, Brown JK et al. Leukotriene B4, an activation product of mast cells, is a chemoattractant for their progenitors. J. Exp. Med. 201(12), 1961-1971 (2005).
83. Centers for Disease Control. Asthma prevalence and control characteristics by race/ethnicity - United States, 2002. MMWR Morb. Mortal Wkly Rep. 53, 145-148 (2004).
84. Chavis C, Van Vyve T, Chanez P et al. Leukotriene E4 plasma levels in adult asthmatic patients with variable disease severity. Allergy 52(5), 589-592 (1997).
85. Manning PJ, Rokach J, Malo JL et al. Urinary leukotriene E4 levels during early and late asthmatic responses. J. Allergy Clin. Immunol. 86(2), 211-220 (1990).
86. Kumlin M, Dahlen B, Bjorck T, Zetterstrom O, Granstrom E, Dahlen SE. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am. Rev. Respir. Dis. 146(1), 96-103 (1992).
87. Kikawa Y, Miyanomae T, Inoue Y et al. Urinary leukotriene E4 after exercise challenge in children with asthma. J. Allergy Clin. Immunol. 89(6), 1111-1119 (1992).
88. Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 279(15), 1181-1186 (1998). (Pubitemid 28193428)
89. Israel E, Rubin P, Kemp JP et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann. Intern. Med. 119(11), 1059-1066 (1993).
90. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebocontrolled trial. Ann. Intern. Med. 126(3), 177-183 (1997).
91. Kemp JP, Dockhorn RJ, Shapiro GG et al. Montelukast once daily inhibits exerciseinduced bronchoconstriction in 6- to 14-year-old children with asthma. J. Pediatr. 133(3), 424-428 (1998).
92. Villaran C, O'Neill SJ, Helbling A et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/ Salmeterol Exercise Study Group. J. Allergy Clin. Immunol. 104(3 Pt 1), 547-553 (1999).
93. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics 107(2), 381-390 (2001).
94. Lima JJ. Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol. Diagn. Ther. 11(2), 97-104 (2007).
95. Szefler SJ, Phillips BR, Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 115(2), 233-242 (2005).
96. In KH, Asano K, Beier D et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J. Clin. Invest. 99(5), 1130-1137 (1997).
97. Drazen JM, Yandava CN, Dube L et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 22(2), 168-170 (1999).
98. Lima JJ, Zhang S, Grant A et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir. Crit. Care Med. 173(4), 379-385 (2006).
99. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237(4819), 1171-1176 (1987).
100. Styles LA, Schalkwijk CG, Aarsman AJ, Vichinsky EP, Lubin BH, Kuypers FA. Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood 87(6), 2573-2578 (1996).
101. Styles LA, Aarsman AJ, Vichinsky EP, Kuypers FA. Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. Blood 96(9), 3276-3278 (2000).
102. Ballas SK, Files B, Luchtman-Jones L et al. Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome. Hemoglobin 30(2), 165-170 (2006).
103. Mollapour E, Porter JB, Kaczmarski R, Linch DC, Roberts PJ. Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease. Blood 91(9), 3423-3429 (1998).
104. Haynes J Jr, Obiako B. Activated polymorphonuclear cells increase sickle red blood cell retention in lung: role of phospholipids. Am. J. Physiol. Heart Circ. Physiol. 282(1), H122-H130 (2002).
105. Haynes J Jr, Obiako B, King JA, Hester RB, Ofori-Acquah S. Activated neutrophilmediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells. Am. J. Physiol. Heart Circ. Physiol. 291(4), H1679-H1685 (2006).
106. Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat. Rev. Genet. 6(2), 109-118 (2005).
107. Ioannidis JP, Trikalinos TA, Khoury MJ. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am. J. Epidemiol. 164(7), 609-614 (2006).